SciBase announces exclusive distribution agreement for Belgium with Dermat Medical Supplies
SciBase, a leader in skin cancer detection technology with its unique point-of-care device Nevisense, continues to expand in Europe with the announcement today that it has entered into an exclusive agreement with Dermat Medical Supplies N.V. for the distribution of Nevisense in Belgium. Dermat Medical Supplies is one of Belgiums main suppliers of medical equipment and devices to dermatologists.
Nevisense is an important new tool for the detection of malignant melanoma, the most fatal form of skin cancer. The ability of Nevisense to accurately detect melanoma has been proven in the world’s largest prospective study of its kind, published earlier this year in the British Journal of Dermatology. Already launched in Australia, Germany, UK, the Nordic markets and now also in Belgium, Nevisense has attracted widespread interest amongst dermatologists as the first non-visual melanoma detection system, using Electrical Impedance Spectroscopy (EIS) to objectively analyze lesions with suspicion of melanoma.
“We are delighted to bring Dermat Medical Supplies aboard as our distributor for the Belgian market. They have a perfect fit with our strategy to work together with partners committed to the dermatological community, and together we will be able to make Nevisense available for widespread use in the often challenging process to accurately detect melanoma” says Simon Grant, CEO of SciBase.
Editor’s Notes
About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 160,000 new cases of melanoma yearly.
About SciBase and Nevisense
SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of academic research at both Karolinska Institutet Stockholm and SciBase. The device is designed to be used when a clinician chooses to obtain additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result.
A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisense-product and further information is also available on www.scibase.com
- ends –
For more information, please contact:
Simon Grant, CEO, SciBase AB, tel +46 72 887 43 99
email: simon.grant@scibase.se
Steven Decabooter, CEO, Dermat Medical Supplies N.V., tel +32 16 40 05 45
email: steven.decabooter@dermat.be